We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+41.28%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$907M
AUM Growth
+$202M
Cap. Flow
-$185K
Cap. Flow %
-0.02%
Top 10 Hldgs %
41.16%
Holding
93
New
10
Increased
12
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$15.3M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$13.9M
3
KA
Kineta, Inc. Common Stock
KA
+$13.2M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$10.9M
5
MTVA
MetaVia Inc
MTVA
+$10M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$30.5M
2
NKTR icon
Nektar Therapeutics
NKTR
+$28.8M
3
SAGE
Sage Therapeutics
SAGE
+$22M
4
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$18.9M
5
NVAX icon
Novavax
NVAX
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
26
Agenus
AGEN
$326M
$11.3M 1.25%
80,405
– –
IVTY
27
DELISTED
Invuity, Inc
IVTY
$10.5M 1.16%
767,466
+733,266
+2,144% +$8.71M
ADXS
28
DELISTED
Advaxis Inc
ADXS
$9.85M 1.09%
61,394
+7,407
+14% +$1.21M
MTVA
29
MetaVia Inc
MTVA
$10.1M
$9.83M 1.08%
+14
New +$10M
CFRX
30
DELISTED
ContraFect Corporation
CFRX
$9.53M 1.05%
4,801
+3,750
+357% +$7.36M
SYNH
31
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$8.92M 0.98%
200,000
– –
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$8.88M 0.98%
298,870
+197,644
+195% +$4.91M
COLL icon
33
Collegium Pharmaceutical
COLL
$722M
$8.77M 0.97%
455,515
– –
DXCM icon
34
DexCom
DXCM
$33B
$8.77M 0.97%
400,000
– –
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$32B
$8.55M 0.94%
126,120
-74,235
-37% -$5.24M
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$8.15M 0.9%
1,006,128
– –
BOLD
37
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.01M 0.88%
+449,660
New +$6.82M
EBS icon
38
Emergent Biosolutions
EBS
$346M
$7.88M 0.87%
+250,000
New +$7.26M
RARE icon
39
Ultragenyx Pharmaceutical
RARE
$1.27B
$7.86M 0.87%
110,842
– –
ARRY
40
DELISTED
Array Biopharma Inc
ARRY
$7.76M 0.86%
+1,150,000
New +$4.45M
FLGT icon
41
Fulgent Genetics
FLGT
$595M
$7.38M 0.81%
+800,000
New +$7.36M
FWP
42
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$7.12M 0.79%
48,454
– –
SGMO
43
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.49M 0.72%
1,402,331
– –
CRIS icon
44
Curis
CRIS
$2.72M
$6.29M 0.69%
1,205
+617
+105% +$2.26M
ZYNE
45
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$6.27M 0.69%
480,501
– –
SCTL
46
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$5.92M 0.65%
746,201
-121,590
-14% -$975K
CTMX icon
47
CytomX Therapeutics
CTMX
$604M
$5.83M 0.64%
371,636
– –
DERM
48
DELISTED
Dermira, Inc.
DERM
$5.82M 0.64%
172,083
– –
PFNX
49
DELISTED
Pfenex Inc.
PFNX
$5.66M 0.62%
632,559
– –
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.43M 0.6%
+131,858
New +$5.01M
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Cormorant Asset Management held 93 positions worth $907M, up 29% from $705M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management's Q3 2016 filing shows 10 new, 12 increased, 5 reduced and 9 closed positions. Its largest new stake was Clovis Oncology, Inc.: 650,000 shares worth $23.4M. The largest sale was TESARO, Inc., an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q3 2016 buy was Clovis Oncology, Inc.: 650,000 shares worth $23.4M.
  • Cormorant Asset Management added most to MyoKardia, Inc. Common Stock in Q3 2016, an estimated $15.3M increase.
  • Cormorant Asset Management's biggest Q3 2016 reduction was Alnylam Pharmaceuticals, cutting an estimated $5.24M.
  • Cormorant Asset Management fully exited TESARO, Inc. in Q3 2016, selling an estimated $30.5M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $907M portfolio in Q3 2016.
  • Cormorant Asset Management opened 10 new positions and closed 9 in Q3 2016.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $907M.

Based on Cormorant Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.